The Cancer Drug Interactions website was set up in 2017 and is a joint venture between Radboud University Medical Centre in Nijmegen, Netherlands and the University of Liverpool, UK.
Dr Nienke Lankheet
Nienke is a Hospital Pharmacist, specialist in oncology patient care and Clinical Pharmacologist in training at Radboud University Medical Centre in Nijmegen. She obtained her PhD from the Netherlands Cancer Institute in Amsterdam for a research project into the clinical pharmacology of targeted agents in oncology. She is particularly interested in the pharmacology of oncolytics and therapeutic drug monitoring.
Dr Nielka van Erp
Dr Frank Jansman
Frank is a Hospital Pharmacist and Clinical Pharmacologist at the Deventer Teaching Hospital and at the University Groningen. He is particularly interested in pharmacotherapy and pharmaceutical care of cancer patients and in clinical toxicology. Frank is chairman of the Dutch Working Group for Interactions Anticancer Drugs (Dutch Association of Hospital Pharmacists, Dutch Society for Medical Oncology, Haemato Oncology Foundation for Adults in the Netherlands, Dutch Society of Clinical Pharmacology and Biopharmacy) and chairman of the Dutch Working Group for Pharmacotherapy and Drug Information (Royal Dutch Pharmacists Association).
Prof David Burger
David is a Professor of Clinical Pharmacy, Radboud University Nijmegen and is (co-) author of more than 350 publications in this field. The topics of his interest are drug-drug interactions, paediatric pharmacology, therapeutic drug monitoring, and operational research in resource-limited countries. David is member of the Editorial Board of www.hiv-druginteractions.org and www.hep-druginteractions.org and member of the Organizing Committee of the annual International Workshop on Clinical Pharmacology of Antiviral Therapy.
Prof Saye Khoo
Saye is a Professor of Clinical Pharmacology at the University of Liverpool and Honorary Consultant Physician, Royal Liverpool and Broadgreen University Hospitals NHS Trust. His primary research interests centre on the pharmacology of HIV treatment failure, including investigation of drug interactions, the role of therapeutic drug monitoring, population pharmacokinetic modelling, molecular characterisation of drug metabolism and disposition pathways and the role of host genetic variability in influencing drug exposure and response.
(Business Development Manager)
Katie is responsible for fundraising for the team and for developing partnerships and projects which support our mission and ethos. Please contact her at firstname.lastname@example.org if you are interested in supporting us or working with us.